Perrigo Company plc $PRGO Stake Raised by West Tower Group LLC

West Tower Group LLC raised its holdings in Perrigo Company plc (NYSE:PRGO) by 45.1% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 352,522 shares of the company’s stock after acquiring an additional 109,567 shares during the quarter. Perrigo makes up 11.8% of West Tower Group LLC’s holdings, making the stock its 2nd largest holding. West Tower Group LLC owned about 0.26% of Perrigo worth $3,786,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. EverSource Wealth Advisors LLC raised its position in Perrigo by 116.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after purchasing an additional 1,014 shares in the last quarter. Geneos Wealth Management Inc. lifted its holdings in Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after buying an additional 786 shares during the period. UMB Bank n.a. boosted its position in Perrigo by 161.5% during the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after acquiring an additional 1,213 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in Perrigo during the 4th quarter valued at $28,000. Finally, CWM LLC increased its holdings in shares of Perrigo by 230.0% in the 4th quarter. CWM LLC now owns 2,191 shares of the company’s stock valued at $31,000 after acquiring an additional 1,527 shares during the period. Institutional investors own 95.91% of the company’s stock.

Perrigo Stock Performance

Shares of PRGO opened at $11.20 on Wednesday. The company has a current ratio of 2.72, a quick ratio of 1.59 and a debt-to-equity ratio of 1.45. The firm has a market cap of $1.55 billion, a PE ratio of -0.86, a P/E/G ratio of 1.32 and a beta of 0.51. Perrigo Company plc has a 12 month low of $9.23 and a 12 month high of $28.43. The stock has a fifty day moving average price of $10.86 and a 200-day moving average price of $12.08.

Perrigo (NYSE:PRGO) last announced its earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.04. The company had revenue of $841.80 million for the quarter, compared to analyst estimates of $1.04 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The firm’s quarterly revenue was down 7.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.60 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Equities research analysts predict that Perrigo Company plc will post 2.11 earnings per share for the current fiscal year.

Perrigo Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Investors of record on Friday, May 29th were paid a $0.29 dividend. The ex-dividend date was Friday, May 29th. This represents a $1.16 dividend on an annualized basis and a yield of 10.4%. Perrigo’s dividend payout ratio (DPR) is -8.85%.

Analysts Set New Price Targets

Several research firms have issued reports on PRGO. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings raised shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $19.33.

Perrigo Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.